Skip to content
mapperlab
← Dashboard
Stock

LXEO

Lexeo Therapeutics, Inc.
Latest close $4.716 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
6
27 funds tracked
Ever held
8
Current + past
New this quarter
0
Exited this quarter
1

Marquee-fund ownership over time

Feb 14, 2024Feb 14, 2025Nov 14, 2025May 14, 2026
Now
6

This quarter's activity

New positions opened

None.

Positions exited

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Citadel Advisors$12$4.71-60%
Millennium Management$12$4.71-60%
Point72 Asset Management$7.78$4.71-39%
AQR Capital Management$4.50$4.71+5%
Two Sigma Investments$2.70$4.71+74%
D.E. Shaw$9.04$4.71-48%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Past holders

Funds that exited at some point
FundEntry → ExitReturn
Renaissance Technologies→ $5.50+104%
D1 Capital Partners→ $6.28-58%

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at Lexeo Therapeutics, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
3
Filings · last 90d
9
Total on file
82
Recent SEC buffer
Most recent
May 20, 2026

30d / 90d windows measured from May 20, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 82 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · Lexeo Therapeutics, Inc.

Annual figures sourced directly from Lexeo Therapeutics, Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Net income
-$99.96M
FY2025-2% YoY
EPS (diluted)
$-1.86
FY2025+40% YoY
Free cash flow(?)
-$98.96M
FY2025-21% YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for Lexeo Therapeutics, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
D.E. ShawQ4 2025open$9.04$4.71-48%
Two Sigma InvestmentsQ2 2025open$2.70$4.71+74%
Renaissance TechnologiesQ2 2025Q2 2026$2.69$5.50+104%
AQR Capital ManagementQ1 2025open$4.50$4.71+5%
Point72 Asset ManagementQ4 2024open$7.78$4.71-39%
Citadel AdvisorsQ3 2024open$12$4.71-60%
Millennium ManagementQ3 2024open$12$4.71-60%
D1 Capital PartnersQ1 2024Q1 2026$15$6.28-58%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.